CA-GLOBALLOGIC
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced availability of technology accelerators that significantly reduce time to market of custom Over-The-Top (OTT) applications by as much as 30 to 50 percent. This is accomplished through the development of advanced solution accelerators for application development and testing across all major mainstream OTT platforms. GlobalLogic delivers this capability through a software engineering team with deep expertise in the end-to-end OTT value chain, which has developed more than 200 complex applications over the past ten years as part of multiple global OTT services rollouts.
OTT Digital Accelerators
The world of streaming applications has become immense and complex. Consumers demand high-quality, immersive viewing experiences from any provider on any device. To satisfy this demand and increase consumer engagement, OTT service providers must develop extremely efficient, native application experiences across multiple platforms, including living room (Smart TV, Streaming Device), mobile, web and gaming environments. Streaming applications must be highly reliable and resilient, to assure content will be available 24/7. And systems must be robust to enable providers to monetize the service. Global rollouts add additional complexity to the entire development process.
Over the last ten years, GlobalLogic has been delivering custom OTT platform application development services for more than 20 streaming platform customers—resulting in the creation of best practice frameworks and accelerators for faster development of OTT services. The GlobalLogic OTT Channel Development Accelerator and TestLab are two such accelerators enabling GlobalLogic customers such as media companies to create exceptionally reliable, immersive experiences for consumers.
The accelerators are platform-agnostic—compatible with the most commonly used consumer streaming services—as well as device-agnostic, supporting gaming consoles, set-top boxes, smartphones, PCs, and tablets. They also support management of multiple devices from a single interface.
OTT Channel Development Accelerator : A customizable media platform that enables the creation of a fully functional, completely branded OTT channel or app from idea to launch-ready in just 2.5 months.1
Key Features and Benefits:
- Common code base for native applications on similar platforms
- Support for all VOD models (AVOD, SVOD, TVOD)
- Advanced, customizable UI/UX features such as unlimited screens or background video
- Versatile monetization options such as in-app purchases, subscription billing, or ad-based services
- Code base owned by client with flexible GlobalLogic engagement models
OTT TestLab Accelerator : A unified infrastructure that schedules automated quality assurance tests on all OTT devices. Clients can test on their own devices, or leverage GlobalLogic’s devices and labs. This is further enhanced by custom, automated test cases for all major platforms and use cases.
Key Features and Benefits:
- Makes testing possible as soon as channel development project begins
- Jump starts continuous integration/continuous delivery (CI/CD) pipelines
- Simple KPI set up and viewing with easy app adjustment capabilities based on results
- Eliminates need to purchase duplicate equipment dedicated to each device
- 3,000+ test devices spanning all major platforms, vendors, use-cases
“The OTT application landscape has grown dramatically larger and more complex over the past few years, and our clients are seeking partners to help navigate it,” said Arun Mukunda, VP and Global Head, Media and Entertainment, GlobalLogic. “Having delivered hundreds of complex OTT applications, GlobalLogic is in a unique position to help our clients rapidly create and launch high quality streaming services on a global scale at a pace never before possible.”
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
1 Approximate time frame based on building and launching a standard app. More complex apps may take longer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005382/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
